Medscape InDiscussion: Breast Cancer and HER2
Medscape InDiscussion: Breast Cancer and HER2 is a podcast series where thought leaders and clinical experts share insights and practical ideas for optimizing patient care. It focuses on breast cancer and HER2, with discussions planned, produced, and reviewed independently of advertisers. The podcast is intended only for US healthcare professionals. Relevant disclosures are available in the episode show notes on Medscape.
Episodes
S2 Episode 6: Beyond pCR Rates in Breast Cancer and HER2: Understanding Response, Residual Disease, and Outcomes
Drs Kathy Miller and Lajos Pusztai discuss predicting which patients will have a PCR, and the impact this has on new treatments or reducing the intensity of treatments. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002987. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is in
S2 Episode 5: HER2 Positive, Low, Ultralow: What Testing Means in the ADC Era
Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002986. The topics and discussions are planned, produced, and reviewed independently of advertisers. Th
S2 Episode 4: ILD and ADCs in the Treatment of Breast Cancer and HER2: Early Symptoms, Pulmonary Collaboration, and Ongoing Vigilance
Drs Kathy Miller and Erika Hamilton discuss ILD linked to ADCs, highlighting early symptoms, key CT findings, pulmonary collaboration, steroid management, and ongoing vigilance. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002985. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podc
S2 Episode 3: Recent Changes in the Management of Metastatic HER2-Positive Breast Cancer
Drs Kathy Miller and Sara Tolaney discuss changes in the management of first-line metastatic HER2-positive disease and the DESTINY-Breast09 trial results. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002984. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only fo
S2 Episode 2: Addressing Common Toxicities for Breast Cancer HER2-Targeted Therapies
Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for U
S2 Episode 1: Cardiac Toxicity and HER2-Targeted Therapy: Who's at Risk?
Drs Kathy Miller and Bonnie Ky discuss cardiovascular concerns with HER2-targeted therapies and how to work with cardiology colleagues for the best treatment outcomes. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is int
S1 Episode 6: New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?
Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2–ultra-low breast cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001338. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcar
S1 Episode 5: Shared Decision-Making in Sequencing ADCs for HER2-Low Breast Cancer
Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is in
S1 Episode 4: Managing Central Nervous System Metastasis in Patients With HER2-Positive Breast Cancer
Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended onl
S1 Episode 3: Evolving Conversations in HER2+ Oligometastatic Breast Cancer Management
Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and
S1 Episode 2: Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?
Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended o
S1 Episode 1: Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and Toxicity
Drs Kathy D. Miller and Sara M. Tolaney discuss advancements and considerations for optimizing treatment for HER2-positive breast cancer, focusing on balancing efficacy with minimizing toxicity. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of adver
